<DOC>
	<DOCNO>NCT00351637</DOCNO>
	<brief_summary>The purpose Phase II study determine feasibility dose titration assessment protocol impatient population , clinical set prevent manage breakthrough pain , conduct appropriately power phase III study . Thus primary purpose study determine proportion patient successfully titrate effective dose sublingual methadone .</brief_summary>
	<brief_title>Sublingual Methadone Management Cancer-related Procedure Pain Inpatients</brief_title>
	<detailed_description />
	<mesh_term>Methadone</mesh_term>
	<criteria>Pain due cancer treatment ; Controlled baseline pain ; episode predictable , treatment related pain every day 4 '' /10 '' severity great , last 10 minute longer , episodes breakthrough pain related cancer treatment , responsive short act oral opioids morphine hydromorphone ; able hold volume 1.0cc water tongue 2minute period ; able provide write informed consent ; able fill study form , inpatient Severe underlie respiratory disease investigator wary risk respiratory failure modest dose od opioid ; prior sensitivity methadone ; currently administered methadone ; clinically unstable life expectancy le one month make completion trial unlikely ; understand English sufficiently provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Sublingual methadone</keyword>
	<keyword>iatrogenic</keyword>
	<keyword>treatment related incident breakthrough pain</keyword>
	<keyword>feasibility study</keyword>
	<keyword>Phase II/open-label</keyword>
	<keyword>inpatient</keyword>
	<keyword>Safety/efficacy</keyword>
	<keyword>Cancer relate breakthrough pain</keyword>
	<keyword>previously receive opioids</keyword>
	<keyword>speak English</keyword>
</DOC>